Patent US4895838A successfully refreshed from Google Patents.
US4895838A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Method for provoking angiogenesis by administration of angiogenically active oligosaccharides
Assignee: ANGIO-MEDICAL Corp 1350 AVENUE OF AMERICAS NEW YORK NEW YORK 10019 A DE CORP
•
Filing: 1988-03-09
•
Granted: 1990-01-23
•
Expires: 2008-03-09
Abstract
Abstract A method for causing or increasing angiogenesis is described. The method involves administering to a subject, such as a human being in need of angiogenesis an angiogenically effective amount of an angiogenically effective, pharmaceutically acceptable oligosaccharide or mixture of oligosaccharides.
Inventors
- 👤 Robert McCluer
- 👤 Nicholas Catsimpoolas
- 👤 Michael Klibaner
- 👤 Ann Griffith
- 👤 Robert Sinn
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-23 18:08
CPC Classifications
A; A61; A61K; A61K31/00; A61K31/70; A61K31/7004; C; C07; C07H; C07H13/00; C07H13/02; C07H13/04; C07H15/00; C07H15/02; C07H15/04; C07H3/00; C07H3/06
Claims Analysis
Total Claims: 23
Claim 1
Independent Claim
28 words
Method for causing or enhancing angiogenesis in a subject in need thereof, comprising administering to said subject an angiogenically effective amount of at least one angiogenically active oligosaccharide.
Claim 2
Dependent Claim
28 words
Method for causing or enhancing angiogenesis in a subject in need thereof, comprising administering to said subject an angiogenically effective amount of at least one angiogenically active oligosaccharide.
Claim 3
Dependent Claim
10 words
Method of claim 1, wherein said oligosaccharide is a tetrasaccharide.
Claim 4
Dependent Claim
23 words
Method of claim 2, wherein said tetrasaccharide is selected from the group consisting of O-α-D-glucopyranosyl-(1→6)-O-α-D-glucopyranosyl-(1.fwdarw.4-O-α-D-glucopyranosyl-(43 4) 1→4)-D-glucose, O-(2-Acetamido-2-deoxy-β-D-glucopyranosyl-(1→4)-O-2 (2-acetamido-2-deoxy-β-D-glucopyranosyl)-(1→4)-O-(2-acetamido-2-deoxy-β-D-glucopyranosyl)-(1→4)2-acetamido-2-deoxy-D-glucose (N,N',N",N'"-Tetraacetyl chitotetraose), and 2-(2-Carbomethoxyethylthio)ethyl-O-α-D-glucopyranosyl-(1→6)-O-α-D-glucopyranosyl-(1→4)-O-α-D-glucopyranosyl-(1.fwdarw.4)-β-D-glucopyranoside.
Claim 5
Dependent Claim
10 words
Method of claim 1, wherein said oligosaccharide is a trisaccharide.
Claim 6
Dependent Claim
24 words
Method of claim 4, wherein said trisaccharide is selected from the group consisting O-(2-acetamido-2-deoxy-β-D-glucopyranosyl-(1→4)-O-(2-acetamido-2-deoxy-β-D-glucopyranosyl)-(1→4)-2-acetamido-2-deoxy-D-glucose (N,N',N"-Triacetyl chitotriose), O-β-D-Galactopyranosyl-(1→4)-O-β-D-galactopyranosyl-(1.fwdarw.4)-D-glucose, Ethyl O-α-D-galactopyranosyl-(1→4)-O-β-D-galactopyranosyl-(1.fwdarw.4)β-D-glucopyranoside, Ethyl O-α-D-galactopyranosyl-(1→4)-O-β-D-galactopyranosyl-(1.fwdarw.4)-2-acetamido-2-deoxy-β-D-glucopyranoside, and Methyl O-α-D-mannopyranosyl-(1→6)-[O-α-D-mannopyranosyl-(1.fwdarw.3)-α-D-mannopyranoside.
Claim 7
Dependent Claim
10 words
Method of claim 1, wherein said oligosaccharide is a disaccharide.
Claim 8
Dependent Claim
30 words
Method of claim 6, wherein said disaccharide is selected from the group consisting of Methyl O-β-D-galactopyranosyl-(1→3)-2-acetamido-2-deoxy-β-D-glucopyranoside, Ethyl O-α-D-galactopyranosyl-(1→4)-O-β-D-galactopyranoside, 2-(Octadecylthio)ethyl O-α-D-galactopyranosyl-(1→4)-β-D-galactopyranoside, Methyl O-(2-acetamide-2-deoxy-β-D-galactopyranosyl)-(1→3)-α-D-galactopyranoside, O-(2-Acetamido-2-deoxy-β-D-glucopyranosyl)-(1→4)-2-acetamido-2-deoxy-D-glucose (N,N'-Diacetyl chitobiose), Methyl O-α-D-galactopyranosyl-(1→3)-α-D-galactopyranoside, and Methyl O-α-D-mannopyranosyl-(1→6)-α-D-mannopyranoside.
Claim 9
Dependent Claim
13 words
Method of claim 1, comprising administering a mixture of oligosaccharides to said subject.
Claim 10
Dependent Claim
14 words
Method of claim 8, wherein said mixture of oligosaccharides is derived from human milk.
Claim 11
Dependent Claim
11 words
Method of claim 9, wherein said mixture of oligosaccharides contain lactose.
Claim 12
Dependent Claim
11 words
Method of claim 9, wherein said mixture of oligosaccharides contains lacto-N-neotetraose.
Claim 13
Dependent Claim
11 words
Method of claim 9, wherein said mixture of oligosaccharides contains lactodifucotetraose.
Claim 14
Dependent Claim
13 words
Method of claim 9 wherein said mixture of oligosaccharides contains lacto-N-fuco pentaose II.
Claim 15
Dependent Claim
11 words
Method of claim 1, wherein said subject is a human being.
Claim 16
Dependent Claim
23 words
Method of claim 1, wherein said oligosaccharide is administered in an amount ranging from about 100 μg to about 20 mg per day.
Claim 17
Dependent Claim
11 words
Method of claim 1, wherein said oligosaccharide contains only glucose residues.
Claim 18
Dependent Claim
11 words
Method of claim 1, wherein said oligosaccharide contains only galactose residues.
Claim 19
Dependent Claim
11 words
Method of claim 1, wherein said oligosaccharide contains only mannose residues.
Claim 20
Dependent Claim
20 words
Method of claim 1, wherein said oligosaccharide contains a mixture of at least two of glucose, galactose, and mannose residues.
Claim 21
Dependent Claim
13 words
Method of claim 1, wherein said oligosaccharide is conjugated to bovine serum albumin.
Claim 22
Dependent Claim
28 words
Method of claim 20, wherein said oligosaccharide complexed to obvine serum albumin is selected from the group consisting of O-β-(2-(2-carbomethoxyethylthio)ethyl)-N-acetyl-D-galactosamine; O-β-(2-(2-carboxymethoxyethylthio)ethyl-N-acetyl-D-glucosamine; O-2-(2-carbomethoxylethylthio)ethyl-methyl; and O-β-(2-(2-carboxymethoxyethylthio)ethyl galactose 1→3 N-acetyl glucosamine.
Claim 23
Dependent Claim
23 words
Method of claim 1, wherein said oligosaccharide is a substituted monosaccharide selected from the group consisting of 2-(2-Carbomethoxyethylthio)ethyl-β-D-galactopyranoside, 2-l -(Octadecylthio)ethyl-β-D-galactopyranoside, 2-(2-Carbomethoxyethylthio)ethyl-β-D-glucopyranoside, and 2-(Octadecylthio)ethyl-β-D-glucopyranoside.
References Cited (Backward Citations)
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1993-01-22 | 1993-07-24 | 1994-01-23 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1997-01-22 | 1997-07-24 | 1998-01-23 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2001-01-22 | 2001-07-24 | 2002-01-23 | $7700.00 | Window Closed / Lapsed |